Compare COO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | NBIX |
|---|---|---|
| Founded | 1980 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | COO | NBIX |
|---|---|---|
| Price | $71.05 | $168.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | $90.18 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 3.6M | 1.1M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.27 | ★ 1.91 |
| Revenue | ★ $2,532,800,000.00 | $161,626,000.00 |
| Revenue This Year | $6.66 | $24.73 |
| Revenue Next Year | $5.18 | $13.14 |
| P/E Ratio | $261.30 | ★ $85.87 |
| Revenue Growth | 18.41 | ★ 977.51 |
| 52 Week Low | $58.89 | $122.14 |
| 52 Week High | $89.83 | $169.57 |
| Indicator | COO | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 67.72 | 62.32 |
| Support Level | $67.91 | $153.96 |
| Resistance Level | $72.07 | $169.57 |
| Average True Range (ATR) | 1.84 | 4.79 |
| MACD | 0.48 | -0.19 |
| Stochastic Oscillator | 80.31 | 80.36 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.